Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report

被引：0

作者：

Li, Shuluan ^{[1
,2
]}

Zhang, Pei ^{[3
]}

Wang, Tianyu ^{[2
,4
]}

Wang, Jie ^{[3
]}

Duan, Jianchun ^{[3
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol Natl,Canc Ctr, Shenzhen 100021, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China

[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol,Natl Canc Ctr, Beijing 100021, Peoples R China

[4] Chinese Acad Med Sci & Peking Union Med Coll, Dept Breast Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Shenzhen, Peoples R China

来源：

THORACIC CANCER | 2021年 / 12卷 / 23期

关键词：

ALK; brigatinib; chemotherapy; lung squamous cell carcinoma; 1ST-LINE CRIZOTINIB; OPEN-LABEL; CANCER; ROS1;

D O I：

10.1111/1759-7714.14133

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The definitive efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK positive lung squamous cell carcinoma (sqCC) patients remain unclear. Here, we report a case in which brigatinib had a therapeutic effect on ALK-positive lung squamous cell carcinoma. The patient in this report was diagnosed with ALK-positive lung squamous cell carcinoma with brain metastases, and received brigatinib after failure of first-line chemotherapy. Response duration was approximately 11 months, with tolerable side effects. In conclusion, a good clinical effect was achieved in a patient with ALK positive lung squamous cell carcinoma who received treatment with an ALK inhibitor.

引用

页码：3273 / 3276

页数：4